Dataset Information

Examining self-defining memories and aggression in a sample of criminal offenders.

ABSTRACT: Self-defining memories (SDMs) are a type of autobiographical memory that people use as a narrative way to explain their self-identity. We sought to examine the relationships between SDMs, aggression, and criminality in a sample of men, 18-64 years of age, recruited in Spain. The sample included three groups: incarcerated criminal offenders with mental illness, incarcerated criminal offenders without mental illness, and healthy community controls. Analyses of the relationship between SDMs and criminal status demonstrated that incarcerated offenders, regardless of mental health status, endorsed phenomenological characteristics of SDMs of their transgressive self at a higher level than community controls. Aggression differed across all three groups, such that inmates demonstrated higher levels of trait aggression than community controls. The associations between aggression and age at event of SDMs did not differ between groups. Further investigation of the relationship between SDMs, aggression, and criminal status may augment understanding of factors of criminality.

SUBMITTER: Taple BJ

PROVIDER: S-EPMC6564674 | biostudies-other | 2019 May

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Examining self-defining memories and aggression in a sample of criminal offenders.

Taple Bayley J BJ Zabala-Baños Carmen C Jimeno María V MV Griffith James W JW Ricarte Jorge J JJ

Memory (Hove, England) 20181211 5

Self-defining memories (SDMs) are a type of autobiographical memory that people use as a narrative way to explain their self-identity. We sought to examine the relationships between SDMs, aggression, and criminality in a sample of men, 18-64 years of age, recruited in Spain. The sample included three groups: incarcerated criminal offenders with mental illness, incarcerated criminal offenders without mental illness, and healthy community controls. Analyses of the relationship between SDMs and cri ...[more]

PMID: 30537898

Similar Datasets

Project description:Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10 or more days of opioid use in a 28-day period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use. Post-treatment follow-up occurred at weeks 27, 52, and 78.A total of 153 participants were assigned to extended-release naltrexone and 155 to usual treatment. During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to relapse than did those assigned to usual treatment (10.5 vs. 5.0 weeks, P<0.001; hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.68), a lower rate of relapse (43% vs. 64% of participants, P<0.001; odds ratio, 0.43; 95% CI, 0.28 to 0.65), and a higher rate of opioid-negative urine samples (74% vs. 56%, P<0.001; odds ratio, 2.30; 95% CI, 1.48 to 3.54). At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negative urine samples were equal (46% in each group, P=0.91). The rates of other prespecified secondary outcome measures--self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration--were not significantly lower with extended-release naltrexone than with usual treatment. Over the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group and seven in the usual-treatment group (P=0.02).In this trial involving criminal justice offenders, extended-release naltrexone was associated with a rate of opioid relapse that was lower than that with usual treatment. Opioid-use prevention effects waned after treatment discontinuation. (Funded by the National Institute on Drug Abuse; ClinicalTrials.gov number, NCT00781898.).

Project description:INTRODUCTION:Aggression is a clinical symptom of various psychiatric disorders that can be conceptualised as a physical act towards another person with the intent to cause harm. In antisocial personality disorder (ASPD), aggression is a frequent manifestation that differently compromise therapeutic and prognostic goals according to its impulsive or premeditated categorisation. ASPD is characterised by high levels of impulsivity, psychopathic traits, and a high prevalence of co-morbid substance use disorders (SUDs). Aggression in ASPD patients may determine long and recurrent imprisonment thus representing a challenge clinicians and legal experts face. OBJECTIVES:Our aims were to characterise impulsive and premeditated aggression in male ASPD offenders as well as to determine the potential role of SUDs, impulsivity, and psychopathic traits as predictors. MATERIALS AND METHODS:In this cross-sectional study we evaluated a sample of ASPD offenders with a battery of clinical and psychometric, standardised instruments: the Psychopathy Checklist-Revised (PCL-R), the European Version of the Addiction Severity Index (EuropASI), the Barratt Impulsivity Scale Version 11 (BIS-11), and the Impulsive/Premeditated Aggression Scale (IPAS). RESULTS:We used a total sample of 134 offenders, all of whom were male. ASPD patients (n = 96) had a 71.9% prevalence of impulsive aggression and a 28.1% prevalence of premeditated aggression. ASPD patients with impulsive aggression had significantly lower scores of total PCL-R (p<0.01) factor 1 and interpersonal facet 1 (p<0.05), compared with ASPD patients with premeditated aggression. ASPD patients with impulsive aggression and ASPD patients with premeditated aggression had comparable BIS-11 mean scores, and exhibited an equal prevalence of SUDs. The interpersonal facet 1of the PCL-R predicted the aggression type (p<0.05) in ASPD patients, and the exponential beta value for facet 1 was 1.42 (CI = 1.03; 1.95). CONCLUSIONS:The aggression type that is associated with ASPD is mainly impulsive in nature. ASPD patients who have higher scores of psychopathic traits have a lower probability of exhibiting impulsive aggression and a higher probability of exhibiting premeditated aggression. Although ASPD patients have high levels of impulsivity and a high frequency of SUDs, these two variables were not predictors of the aggression type.

Dataset Information

Examining self-defining memories and aggression in a sample of criminal offenders.

Publications

Examining self-defining memories and aggression in a sample of criminal offenders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure